Results 151 to 160 of about 39,064 (303)

First‐line treatment of osteoporosis with osteoanabolic therapy: a new opportunity

Internal Medicine Journal, EarlyView.
Abstract Osteoporosis is a national health priority, and over six million Australians over the age of 50 years have poor bone health. Fragility fractures due to osteoporosis are associated with an increased morbidity and mortality risk and a high economic cost to the community. It is a chronic condition requiring long‐term management.
Jasna Aleksova, Peter Ebeling
wiley   +1 more source

Drug survival of IL‐23 and IL‐17 inhibitors versus other biologics for psoriasis: A British Association of Dermatologists Biologics and Immunomodulators Register cohort study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Psoriasis affects 2–3% of the population, with numerous biologic options complicating treatment selection. This real‐world study found IL‐23p19 inhibitors offer the longest‐lasting effectiveness and safety. Psoriatic arthritis reduced ustekinumab survival, and prior biologic use impacted persistence, especially for IL‐17 inhibitors.
Leila Motedayen Aval, Zenas Z. N. Yiu, Oras A. Alabas, Christopher E. M. Griffiths, Nick J. Reynolds, Philip J. Hampton, Catherine H. Smith, Richard B. Warren, BADBIR Study Group   +8 more
wiley   +1 more source

Budget impact analysis of the incorporating of biosimilars in a cancer institute of a philanthropic hospital

Revista Brasileira de Farmácia Hospitalar e Serviços de Saúde
Objective: Global healthcare costs continue to rise annually, and this is a major challenge given the scarce resources and growing prices of innovative drugs. An interesting alternative for reducing costs is the use of biosimilars.
Maria Luísa BRODT-LEMES, Diana Saiara BRUSCATO, Douglas Silva MADRUGA, Joice SMANIOTTO, Julia Roberta SAGGIORATO-LUBIAN, Letícia Tramontina DE-VILLA, Suhélen CAON, Thamyrys Bessa SILVA   +7 more
doaj   +1 more source

The Portuguese Society of Rheumatology position paper on the use of biosimilars [PDF]

, 2014
Biotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs intended to be as efficacious ...
Aguiar, R, Ambrósio, C, André, R, Araújo, F, Barcelos, F, Bernardes, M, Bogas, M, Canhão, H, Castelão, W, Coelho, PC, Cordeiro, I, Costa, L, Cunha, I, Duarte, C, Faustino, A, Fernandes, S, Fonseca, JE, Garcês, S, Gonçalves, J, Las, V, Leitão, R, Malcata, A, Maurício, L, Meirinhos, T, Melo-Gomes, JA, Miguel, C, Miranda, LC, Monteiro, P, Neto, A, Pereira da Silva, JA, Pimenta, S, Pimentel-Santos, FM, Pimentão, JB, Ramiro, Sofia, Ramos, JC, Roxo, Ana, Santos, H, Sepriano, A, Silva, C, Silva, M, Tavares, V, Teixeira, F   +41 more
core  

Competitive Entry in the Market for Branded Generic Drugs

Journal of Economics &Management Strategy, EarlyView.
ABSTRACT I analyze the determinants of lead time (the time lag between the first‐mover's product release and the competitor's market entry) and its consequences for product prices, competition, and consumers. I investigate the case for the Indian branded generic pharmaceutical sector where substantial variation in lead time is observed.
Vasudha Wattal
wiley   +1 more source

Effects of Adalimumab-adbm Versus Adalimumab Reference Product on Patient-Reported Outcomes in Rheumatoid Arthritis: Results from VOLTAIRE-RA

Rheumatology and Therapy
Introduction This post hoc analysis of VOLTAIRE-RA compared patient-reported outcomes, including health-related quality of life (HRQoL), in patients with rheumatoid arthritis (RA) before and after treatment with biosimilar adalimumab-adbm or adalimumab ...
Vibeke Strand, Shaun Bender, Dorothy McCabe   +2 more
doaj   +1 more source

The Role of Recombinant Human Growth Hormone Biosimilars in the Management of Growth Disorders [PDF]

, 2009
T E Romer
openalex   +1 more source

Glycosimilarity assessment of biotherapeutics 1: quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept [PDF]

, 2018
K
Borza, Beáta, Guttman, András, Hajba, László, Szekrényes, Ákos, Szigeti, Márton   +4 more
core  

Phenotypic Differences and Clinical Outcomes of South Asian Children With IBD: A Singapore–Malaysia Study From the Asian PIBD Registry Network

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Background and Aim Existing literature largely contrasts pediatric inflammatory bowel disease (PIBD) phenotypic differences and outcomes of South Asians (SAs) with Caucasians. No published comparative data exist between SAs and non‐SAs within Asia‐Pacific.
James Guoxian Huang, Kee Seang Chew, Veena Logarajah, Way Seah Lee, Marion Margaret Aw   +4 more
wiley   +1 more source

Healthy volunteer stem cell donors followed up 10 years after stimulation with biosimilar filgrastim

Transfusion, EarlyView.
Abstract Background The application of granulocyte colony‐stimulating factors (G‐CSF) for mobilizing hematopoietic stem and progenitor cells in healthy donors is considered safe. However, only limited safety information is available about long‐term adverse events (AEs) in this setting.
Jens Heyn, Susanne Bräuninger, Petra Becker, Niklas Stoeckmann, Christian Seidl, Sebastian Howe, Simon Daubert, Daniel Fürst, Hubert Schrezenmeier, Halvard Bonig   +9 more
wiley   +1 more source